Status:
COMPLETED
Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV
Lead Sponsor:
University of Florida
Collaborating Sponsors:
Consortium for Medical Marijuana Clinical Outcomes Research
Conditions:
Chronic Inflammation
Eligibility:
All Genders
21-60 years
Phase:
PHASE4
Brief Summary
People living with HIV (PLWH) are affected by comorbidities appearing to be strongly related to chronic inflammation, a condition characterizing PLWH. The investigators propose to study the effects o...
Eligibility Criteria
Inclusion
- Willingness to take CBD and to participate in follow up for two months
- Older than 21 and younger than 60
- Under antiretroviral therapy for 5+ years and suppressed viral load (CD4 count \<350cells/ml)
Exclusion
- Conditions/medications that may impair the immune response, e.g., rheumatoid arthritis, cancer, diabetes, chronic infections, CAD (Cold agglutinin disease), cellulitis, autoimmune diseases such as lupus, sarcoidosis
- All medications that may affect inflammation such as aspirin, steroids, statins; CD4 count \<350cells/ml), pregnancy, and current marijuana or CBD use (urine drug screen)
- UF(University of Florida)/Shands staff and students will not be considered for enrollment
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 12 2022
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT05209867
Start Date
May 1 2022
End Date
December 12 2022
Last Update
December 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Gainesville, Florida, United States, 32610